TNSN00226A1 - Composes morpholiniques antagonistes du recepteur de la nk-1 - Google Patents

Composes morpholiniques antagonistes du recepteur de la nk-1

Info

Publication number
TNSN00226A1
TNSN00226A1 TNTNSN00226A TNSN00226A TNSN00226A1 TN SN00226 A1 TNSN00226 A1 TN SN00226A1 TN TNSN00226 A TNTNSN00226 A TN TNSN00226A TN SN00226 A TNSN00226 A TN SN00226A TN SN00226 A1 TNSN00226 A1 TN SN00226A1
Authority
TN
Tunisia
Prior art keywords
morpholinic
compounds
receptor antagonist
receptor
compound
Prior art date
Application number
TNTNSN00226A
Other languages
English (en)
French (fr)
Inventor
Maria Ballard Theresa
Sleight Andrew
Andrew Higgins Guy
Hoffmann Torsten
Maria Poli Sonia
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of TNSN00226A1 publication Critical patent/TNSN00226A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
TNTNSN00226A 1999-11-29 2000-11-29 Composes morpholiniques antagonistes du recepteur de la nk-1 TNSN00226A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99123685 1999-11-29

Publications (1)

Publication Number Publication Date
TNSN00226A1 true TNSN00226A1 (fr) 2002-05-30

Family

ID=8239481

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN00226A TNSN00226A1 (fr) 1999-11-29 2000-11-29 Composes morpholiniques antagonistes du recepteur de la nk-1

Country Status (49)

Country Link
EP (1) EP1103545B1 (enExample)
JP (1) JP3480835B2 (enExample)
KR (1) KR100390117B1 (enExample)
CN (1) CN1152016C (enExample)
AR (1) AR033659A1 (enExample)
AT (1) ATE253561T1 (enExample)
AU (1) AU775292B2 (enExample)
BG (1) BG64622B1 (enExample)
BR (1) BRPI0005616B8 (enExample)
CA (1) CA2326529C (enExample)
CO (1) CO5251405A1 (enExample)
CZ (1) CZ299286B6 (enExample)
DE (2) DE60006340T2 (enExample)
DK (1) DK1103545T3 (enExample)
DO (1) DOP2000000106A (enExample)
EA (1) EA004404B1 (enExample)
ES (2) ES2208205T3 (enExample)
FR (1) FR2801590A1 (enExample)
GB (1) GB2356863A (enExample)
GC (1) GC0000151A (enExample)
GE (1) GEP20022763B (enExample)
GT (1) GT200000197A (enExample)
HR (1) HRP20000809A2 (enExample)
HU (1) HU224703B1 (enExample)
ID (1) ID28483A (enExample)
IL (1) IL139868A (enExample)
IS (1) IS2212B (enExample)
IT (1) IT1320120B1 (enExample)
JO (1) JO2298B1 (enExample)
MA (1) MA26754A1 (enExample)
MX (1) MXPA00011672A (enExample)
MY (1) MY127426A (enExample)
NO (1) NO317264B1 (enExample)
NZ (1) NZ508386A (enExample)
OA (1) OA11513A (enExample)
PA (1) PA8507201A1 (enExample)
PE (1) PE20010901A1 (enExample)
PL (1) PL195957B1 (enExample)
PT (1) PT1103545E (enExample)
SG (1) SG97171A1 (enExample)
SI (1) SI1103545T1 (enExample)
SK (1) SK285373B6 (enExample)
SV (1) SV2002000227A (enExample)
TN (1) TNSN00226A1 (enExample)
TR (1) TR200302077T4 (enExample)
UA (1) UA70326C2 (enExample)
UY (1) UY26458A1 (enExample)
YU (1) YU73400A (enExample)
ZA (1) ZA200006964B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL144717A0 (en) 1999-02-24 2002-06-30 Hoffmann La Roche Phenyl-and pyridinyl derivatives
EP1035115B1 (en) * 1999-02-24 2004-09-29 F. Hoffmann-La Roche Ag 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
PT1303490E (pt) * 2000-07-14 2008-09-04 Hoffmann La Roche Óxidos de aminas como pró-fármacos de antagonistas dosreceptores nk1, de derivados de 4-fenil-piridina
TWI287003B (en) * 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
TWI259180B (en) * 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
US20030083345A1 (en) * 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury
KR20040077910A (ko) * 2002-01-31 2004-09-07 에프. 호프만-라 로슈 아게 프리프로타키키닌 유전자의 유전자 다형성
ES2291891T3 (es) 2003-07-03 2008-03-01 F. Hoffmann-La Roche Ag Antagonistas duales de nk1/nk3 para tratamiento de esquizofrenia.
US7288658B2 (en) 2003-07-15 2007-10-30 Hoffmann-La Roche Inc. Process for preparation of pyridine derivatives
CN1984891B (zh) 2004-07-06 2012-08-08 弗·哈夫曼-拉罗切有限公司 用作合成nk-1受体拮抗剂的中间体的甲酰胺吡啶衍生物的制备方法
CA2598762A1 (en) 2005-02-25 2006-08-31 F. Hoffmann-La Roche Ag Tablets with improved drug substance dispersibility
CA2602445C (en) 2005-03-23 2013-08-20 F.Hoffmann-La Roche Ag Metabolites for nk-i antagonists for emesis
ATE453384T1 (de) 2005-09-23 2010-01-15 Hoffmann La Roche Neue dosierformulierung
US8093268B2 (en) 2007-01-24 2012-01-10 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-)
US8426450B1 (en) 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
BR112015021982B1 (pt) 2013-03-15 2022-12-13 Global Blood Therapeutics, Inc Compostos e seus usos para a modulação de hemoglobina
CA2930008A1 (en) 2013-11-08 2015-05-14 Kissei Pharmaceutical Co., Ltd. Carboxymethyl piperidine derivative
AP2016009261A0 (en) 2014-02-07 2016-06-30 Global Blood Therapeutics Inc Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
KR101948238B1 (ko) 2016-08-19 2019-02-14 (주)케어젠 미녹시딜과 펩타이드의 결합체
KR102328682B1 (ko) 2018-08-27 2021-11-18 주식회사 대웅제약 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2149767T5 (es) * 1991-09-20 2005-06-16 Glaxo Group Limited Nuevo uso medico para antagonistas de taquiquininas.
CA2099233A1 (en) * 1992-06-29 1993-12-30 Conrad P. Dorn Morpholine and thiomorpholine tachykinin receptor antagonists
IL111960A (en) * 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
IL112134A (en) * 1993-12-29 1999-12-22 Merck Sharp & Dohme Substituted morpholine derivatives their preparation and pharmaceutical compositions containing them
IL112778A0 (en) * 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
EP0733632B1 (en) * 1995-03-24 2003-06-04 Takeda Chemical Industries, Ltd. Cyclic compounds, their production and use as tachykinin receptor antagonists
US5972938A (en) * 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
EP1035115B1 (en) * 1999-02-24 2004-09-29 F. Hoffmann-La Roche Ag 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
US6303790B1 (en) * 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
PT1303490E (pt) * 2000-07-14 2008-09-04 Hoffmann La Roche Óxidos de aminas como pró-fármacos de antagonistas dosreceptores nk1, de derivados de 4-fenil-piridina
TWI287003B (en) * 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
TWI259180B (en) * 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives

Also Published As

Publication number Publication date
IL139868A0 (en) 2002-02-10
IL139868A (en) 2009-09-01
PL344147A1 (en) 2001-06-04
AR033659A1 (es) 2004-01-07
KR20010051983A (ko) 2001-06-25
GB2356863A (en) 2001-06-06
PA8507201A1 (es) 2002-02-21
CN1152016C (zh) 2004-06-02
GB0028566D0 (en) 2001-01-10
TR200302077T4 (tr) 2004-01-21
PL195957B1 (pl) 2007-11-30
EP1103545A1 (en) 2001-05-30
SK285373B6 (sk) 2006-12-07
AU7178700A (en) 2001-05-31
HU0004725D0 (enExample) 2001-02-28
JO2298B1 (en) 2005-09-12
HRP20000809A2 (en) 2001-12-31
MA26754A1 (fr) 2004-12-20
BRPI0005616B1 (pt) 2017-12-12
YU73400A (sh) 2003-02-28
DE60006340T2 (de) 2004-09-09
GC0000151A (en) 2005-06-29
ZA200006964B (en) 2001-06-05
JP3480835B2 (ja) 2003-12-22
HUP0004725A2 (hu) 2002-04-29
GT200000197A (es) 2002-05-22
NO20006012D0 (no) 2000-11-28
DOP2000000106A (es) 2002-07-30
ATE253561T1 (de) 2003-11-15
HU224703B1 (en) 2006-01-30
DK1103545T3 (da) 2004-03-15
ES2208205T3 (es) 2004-06-16
NO20006012L (no) 2001-05-30
JP2001151754A (ja) 2001-06-05
NO317264B1 (no) 2004-09-27
BR0005616A (pt) 2001-07-17
ES2171134A1 (es) 2002-08-16
ID28483A (id) 2001-05-31
OA11513A (fr) 2004-02-03
PE20010901A1 (es) 2001-09-20
ITMI20002575A1 (it) 2002-05-29
MY127426A (en) 2006-11-30
GEP20022763B (en) 2002-08-26
EA200001114A2 (ru) 2001-08-27
SK17932000A3 (sk) 2001-11-06
UA70326C2 (en) 2004-10-15
CZ299286B6 (cs) 2008-06-04
UY26458A1 (es) 2001-05-31
CO5251405A1 (es) 2003-02-28
DE60006340D1 (de) 2003-12-11
SI1103545T1 (en) 2004-02-29
SG97171A1 (en) 2003-07-18
CA2326529A1 (en) 2001-05-29
CN1297888A (zh) 2001-06-06
HK1036759A1 (en) 2002-01-18
AU775292B2 (en) 2004-07-29
CZ20004399A3 (cs) 2001-07-11
SV2002000227A (es) 2002-02-05
FR2801590A1 (fr) 2001-06-01
BG64622B1 (bg) 2005-09-30
BG104992A (en) 2001-11-30
EP1103545B1 (en) 2003-11-05
NZ508386A (en) 2003-02-28
CA2326529C (en) 2009-12-22
KR100390117B1 (ko) 2003-07-04
MXPA00011672A (es) 2002-08-20
BRPI0005616B8 (pt) 2021-07-06
IT1320120B1 (it) 2003-11-18
IS2212B (is) 2007-02-15
PT1103545E (pt) 2004-03-31
IS5725A (is) 2001-05-29
EA004404B1 (ru) 2004-04-29
DE10058310A1 (de) 2001-05-31
EA200001114A3 (ru) 2001-12-24

Similar Documents

Publication Publication Date Title
MA26754A1 (fr) Composes morpholiniques antagonistes du recepteur de la nk-1.
MA27557A1 (fr) Derives d'indolyle pyrazinone utiles pour le traitement des maladies et des troubles hyperproliferants associes a l'angiogenese
DK0775129T3 (da) 3-Benzoylbenzofuranderivater som thyroidhormonantagonister
MA26994A1 (fr) Quinazolines en tant qu'inhibiteurs de la mmp-13
DE69926919D1 (de) N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
DE60220441D1 (de) Substituierte phenylpropionsäurederivate als agonisten des menschlichen peroxisom-proliferator-aktiverten rezeptors alpha(ppar)
EP1040831A3 (en) Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death
EA199700117A1 (ru) Трициклические бензазепиновые антагонисты вазопрессина, способ их получения, фармацевтическая композиция и способ лечения млекопитающих с использованием трициклических бензазепинов
DE69331190D1 (de) Überbrückte azabicyclische derivate als substanz p antagonisten
TNSN02009A1 (fr) Pyrimidinones bicycliques condensees nouvelles, inhibitrices de mmp, et compositions les contenant.
ATE185797T1 (de) Stilben-derivate verwendbar als cyclooxygenase-2 hemmer
TNSN04194A1 (fr) Derives de tropane servant de modulateurs de ccr5
EA199700111A1 (ru) Трициклические бензазепиновые антагонисты вазопрессина
ATE305781T1 (de) Non-peptidische vasopressin via antagonisten
SE9501632D0 (sv) Ball impression coping
BR9813208A (pt) Antagonista receptor de vitronectina
EA200201158A1 (ru) Бициклические циклогексиламины и их применение в качестве антагонистов nmda-рецепторов
TR200000786T2 (tr) Vitronektin reseptör antagonisti
DE60227283D1 (de) Substituierte diketopiperazine als oxytocin-antagonisten
AP2002002387A0 (en) Method of inhibiting amyloid aggregation and imaging amyloid deposits.
MA26953A1 (fr) Derives de pipérazine pontés.
BR9809848A (pt) Composição
DE69839767D1 (de) Verwendung von 15-keto-prostaglandin-e verbindungen als endothelin antagonisten
ATE277893T1 (de) N-(2-phenyl-4-amino-butyl)-1-naphthamide als neurokinin-1 rezeptorantagonisten
BR9807085A (pt) Antagonistas de receptor de il-8